Longleaf Partners ABT trades
Mason Hawkins
Mason Hawkins Abbott Laboratories stake
total: 53
Trades details
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q2
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Mason Hawkins holds 506,914 Abbott Laboratories (ABT) shares with a market value of roughly $46.00M accounting for 4.38% of the overall portfolio. To date, the estimated cost basis is nearly $90.74 for "buy" trades. Longleaf Partners first purchased ABT in 2026 Q2, initially acquiring 506,914 shares.
When did Mason Hawkins buy Abbott Laboratories (ABT)?
Mason Hawkins first invested in Abbott Laboratories (ABT) in 2026 Q2 at the reported quarter-end price of $90.74 per share.
What's the cost basis of Longleaf Partners's ABT stake?
The estimated cost basis for Abbott Laboratories (ABT) stake is around $90.74 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $90.74
Mason Hawkins's historical trades in Abbott Laboratories
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
4.38%
|
506,914
|
$90.74
|
$45,997,376
|
new
|
+4.38%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.